Register for IPO Updates
US IPO Stats
IPO Industry Breakdown
Largest Global IPOs
Largest US IPOs
IPO News Archive
New Ways to Invest in IPOs - IPO ETFs
US IPO Weekly Recap: All natural pet food maker is top dog in a week with three IPOs
Analyst IPO Market Commentary
Every dog has its day, and this week it was Blue Buffalo: the year's
surged over 30%.
All three initial public offerings this week raised more capital than expected as Blue Buffalo priced above its range while Neos and Live Oak offered additional shares. Each had double-digit returns. Signs of investor discipline also surfaced as two companies postponed IPOs this week.
Recent offerings have produced some of the strongest first day returns of 2015. IPOs over the past 30 days have a median first day gain of +26%, compared to a historical average of about +13%. This enthusiasm could revert to the mean, however, as post-IPO follow-through is almost -3% on average.
You're my boy, Blue! All-natural pet food maker is top dog
Blue Buffalo Pet Products
) priced 18% above the midpoint and traded up 36% on its first day. Blue Buffalo boasts a dominant position in the fastest-growing segment of pet food, as well as impressive gross margins (40%) for the industry. Investors appeared to take no issue with insiders cashing out (IPO 100% sold by PE firm Invus and founders). The next fast-growing, high-margin consumer packaged goods IPO was added to the
on Friday: Amplify Snack Brands (
) is set to raise $225 million //in early August//.
Investors pay up and pay attention to ADHD biotech
) gained 30% on its first day and continued to trade up, making it the week's best-performing IPO. Investors likely felt confident purchasing shares alongside well-respected health care investor Deerfield Management. Neos is developing easily swallowed versions of Ritalin, Adderall and Concerta, and plans to have three drug candidates submitted to the FDA for final approval by the end of the third quarter. Neos' positive trading follows that of recent late-stage drug delivery biotechs Collegium (
) and KemPharm (
), both up 60% from the offer price.
Backed by Wellington Management,
Live Oak Bancshares
) priced its upsized IPO at the midpoint and traded up 13% by Friday. The niche lender (veterinarians, dentists, farmers, etc.) has an online model that lends itself to better operating margins.
Two deals postpone: Skyscraper IPO scrapped and heart failure biotech skips a beat
For the second time,
) postponed an IPO of a single-building REIT. Getting investors to buy into a non-growth story is a tall order, even for a 100% leased Class A Boston skyscraper offering a 5.5% annual yield.
) a heart failure biotech backed by cardiologists and founded by the CEO of CareDx (
), officially postponed its $50 million offering.
3 IPOs during the week of July 20, 2015
Deal size ($mm)
IPO price vs. midpoint
Return at 7/24
Neos Therapeutics (
Easily swallowed ADHD meds
Blue Buffalo Pet Products (
All natural pet food
Live Oak Bancshares (
Niche small business lender
Find out why institutional investors rely on Renaissance Capital's
for these IPOs.
Follow us on Twitter (
) for IPO news as it happens and
register for our updates
on the IPO market.
IPO market snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. The Renaissance IPO Index has traded up about 7% year-to-date, compared to 1% for the S&P 500. Renaissance Capital's
(NYSE: IPO) tracks the index, and top
include Alibaba (
), Twitter (
) and Hilton Worldwide (
). After giving up all of its returns last week, the Renaissance International IPO Index is back up to a 6% gain year-to-date, compared to 1% for the ACWX. Renaissance Capital’s International
(NYSE: IPOS) tracks the index, and top
include Altice and Recruit Holdings.
To find out if this is the best ETF for you, visit our
IPO Investing page
Keywords / Tickers:
Recently Priced IPOs
ETF Express Award:
ETFExpress awards are based on a 'peer review system' whereby readers - including institutional and high net worth investors as well as managers and other industry professionals at fund administrators, brokers, custodians and advisers - are invited to elect a 'best in class' in a series of categories via an online survey. In each category, the firms with the most votes at the end of the voting period are subject to a final review by ETFExpress's Senior Editorial team.
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund's average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds.
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios.
Renaissance International IPO Index® (IPOXUS)
is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges.
The S&P 500® Index (SPX) is a stock market index which includes 500 U.S. listed companies and seeks to capture approximately 80% coverage of available U.S. market capitalization.
Risk Disclosure: Investments in the
Renaissance IPO ETF, symbol "IPO"
Renaissance International IPO ETF, symbol "IPOS"
(the "ETFs"), and the
Global IPO Fund, symbol "IPOSX"
(the "Mutual Fund") are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the "Funds") invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.
Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Definitions: The Renaissance IPO Index® is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE or Nasdaq.
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.
Register for Updates
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2016 Renaissance Capital LLC. All rights reserved.